. 2021 Sep 20:1–4. doi: 10.1017/ice.2021.412

Table 1.

Description of Infection Healthcare Personnel

Participant No.	Age	Sex	Symptoms	SARS-CoV-2 Cycle Threshold	Vaccine Status	Time From Second Dose (Days)	No. of Positive Contacts	Serology Within 3 Days of Diagnosis AU/mL^a	Serology Within 3 Days of Diagnosis BAU/mL	Serology After at Least 12 Days of Diagnosis AU/mL^a	Serology After at Least 12 Days of Diagnosis BAU/mL	NGS Findings
1	26	Female	Mild	16	Unvaccinated		NA	NA
2	31	Female	Mild	15	Unvaccinated		NA	NA
3	32	Male	Asymptomatic	16	Unvaccinated		NA	NA
4	46	Female	Mild	27	Unvaccinated		NA	Anti-S negative Anti-N negative				B.1.1.7/501.v1
5	24	Female	Mild	15	Partially vaccinated		NA	NA
6	67	Female	Mild	20.5	Partially vaccinated		NA	Anti-S positive, 1554 Anti-N negative	Anti-S positive, 221			B.1.1.7/501.v1
7	32	Female	Asymptomatic	17	Partially vaccinated	4	0/2	Anti-S positive, 14260 Anti-N negative	Anti-S positive, 2025			B.1.1.7/501.v1
8	67	Female	Asymptomatic	23	Fully vaccinated	9	0/0	Anti-S -positive, 11190 Anti-N negative	Anti-S positive, 1589	Anti-S positive, 6808 Anti-N positive	Anti-S positive, 967	B.1.1.7/501.v1
9	58	Female	Mild	22	Fully vaccinated	11	0/7 Only 6 tested	Anti-S positive, 965 Anti-N negative	Anti-S positive, 137	Anti-S positive, 13045 Anti-N negative	Anti-S positive, 1852	B.1.1.7/501.v1
10	49	Male	Asymptomatic	31	Fully vaccinated	16	0/3 Not tested	Anti-S positive, 12479 Anti-N negative	Anti-S positive, 1772
11	38	Female	Asymptomatic	23	Fully vaccinated	14	0/4 Only 1 tested	Anti-S positive, 4653 Anti-N negative	Anti-S positive, 661	Anti-S positive, 6223 Anti-N positive	Anti-S positive, 884
12	66	Female	Mild	20	Fully vaccinated	20	0/6	NA		Anti-S positive, 21947 Anti-N positive	Anti-S positive, 3116
13	60	Female	Mild	29	Fully vaccinated	20	0/2 Not tested	NA		Anti-S positive, 24616 Anti-N positive	Anti-S positive, 3495	B.1.1.7/501.v1
14	54	Female	Asymptomatic	36	Fully vaccinated	14	1/1	NA
15	41	Male	Asymptomatic	19	Fully vaccinated	10	0/4 Not tested	NA				B.1.1.7/501.v1*

Note. AU/mL; arbitrary units per milliliter; BAU/mL, WHO binding antibody units; NA, not available. NGS, next-generation sequencing

IgG II Quant assay are reported in AU/mL. A conversion factor between AU/mL and BAU/mL has been established as 1 BAU = 0.142 AU. Additional SARS-CoV-2 positive RNA of a seventh employee was also characterized as the same variant based on receptor-binding domain (RBD) sequencing alone without performing whole-genome sequencing (data not shown in the main text)